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Abstract
Patients with lateral epicondylitis (tennis elbow) are frequently treated with corticosteroid injections, in order to relieve pain and diminish
disability. The objective of this review was to evaluate the effectiveness of corticosteroid injections for lateral epicondylitis. Randomised
controlled trials (RCTs) were identified by a highly sensitive search strategy in six databases in combination with reference tracking. Two
independent reviewers selected and assessed the methodological quality of RCTs that included patients with lateral epicondylitis treated with
corticosteroid injection(s), and reported at least one clinically relevant outcome measure. Standardised mean differences were computed for
continuous data and relative risks (RR) for dichotomous data. A best-evidence synthesis was conducted, weighting the studies with respect to
their internal validity, statistical significance, clinical relevance, and statistical power. Thirteen studies consisting of 15 comparisons were
included in the review, evaluating the effects of corticosteroid injections compared to placebo injection (n ¼ 2), injection with local
anaesthetic (n ¼ 5), another conservative treatment (n ¼ 5), or another corticosteroid injection (n ¼ 3). Almost all studies had poor internal
validity scores. For short-term outcomes (#6 weeks), statistically significant and clinically relevant differences were found on pain, global
improvement and grip strength for corticosteroid injection compared to placebo, local anaesthetic and conservative treatments. For inter-
mediate (6 weeks–6 months) and long-term outcomes ($6 months), no statistically significant or clinically relevant results in favour of
corticosteroid injections were found. Although the available evidence shows superior short-term effects of corticosteroid injections for lateral
epicondylitis, it is not possible to draw firm conclusions on the effectiveness of injections, due to the lack of high quality studies. No
beneficial effects were found for intermediate or long-term follow-up. More, better designed, conducted and reported RCTs with intermediate
and long-term follow-up are needed. q 2002 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Lateral epicondylitis (tennis elbow) is a common medical
problem. It is considered to be an overload injury typically
following minor and often unrecognised trauma (micro-
trauma), involving the extensor muscles of the forearm
(Murtagh, 1988).
The annual incidence of this disorder is between 1 and 3%
in the general population (Allander, 1974; Chard and Hazle-
man, 1989; Chop, 1989). In general practice the incidence of
lateral epicondylitis is estimated at 4–7 per 1000 patients per
year (Verhaar, 1992; Hamilton, 1986). The average duration
of a typical episode of lateral epicondylitis is supposed to be
between 6 months and 2 years (Murtagh, 1988; Hudak et al.,
1996).
In Dutch primary care between 14 and 38% of all patients
with lateral epicondylitis are treated with corticosteroid
injections (Verhaar, 1992; Miedema, 1994). It has been
postulated that the effect of corticosteroids is exerted by
suppressing or dispersing the granulomatous response in
traumatised tissue (Yates, 1977) These anti-inflammatory
effects of corticosteroid injections are believed to relieve
pain and diminish disability (Gray and Gottlieb, 1983;
Goldie, 1972).
In a systematic review, Labelle et al. (1992) evaluated the
effectiveness of various treatments for lateral epicondylitis.
The review included five (randomised) clinical trials on
corticosteroid injections published between 1966 and 1990
Pain 96 (2002) 23–40
0304-3959/02/$20.00 q 2002 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.
PII: S0304-3959(01)00388-8
www.elsevier.com/locate/pain
* Corresponding author. Tel.: 131-20-4449657; fax: 131-20-4448181.
E-mail address: n.smidt.emgo@med.vu.nl (N. Smidt).
in French or English. Because of the poor quality of meth-
ods and the contradictory results Labelle et al. (1992)
concluded that there was insufficient scientific evidence
for any particular type of treatment for lateral epicondylitis.
Assendelft et al. (1996) performed a more comprehensive
systematic review. They reviewed 11 articles and concluded
that the existing evidence on the effectiveness of corticos-
teroid injection for lateral epicondylitis was not conclusive.
The methodological quality of the studies was moderate and
most studies were conducted in secondary care. However,
Assendelft et al. (1996) concluded that corticosteroid injec-
tions appear to be relatively safe and seem to have a bene-
ficial short-term effect (2–6 weeks). Since then additional
large RCTs have been published and review methodology
has been further developed. Therefore, an updated systema-
tic review is required (Meade and Richardson, 1997; Hunt
and McKibbon, 1997). The objective of our review is to
determine the short (#6 weeks), intermediate (6 weeks–6
months) and long-term ($6 months) effectiveness of corti-
costeroid injection(s) in patients with lateral epicondylitis,
based on clinically relevant outcome measures.
2. Methods
2.1. Searching
One reviewer (N.S.) searched computerised bibliographi-
cal databases (MEDLINE 01/1966–07/1999, EMBASE 01/
1988–07/1999, CINAHL 01/1982–07/1999) without
language restrictions (Moher et al., 1996; Gregoire et al.,
1995), using the highly sensitive Cochrane Collaboration
search strategy, which aims to identify all randomised
controlled trials (Mulrow and Oxman, 1997; Van Tulder
et al., 1997). Additional specific subject headings and free
text words were used to identify papers on lateral epicondy-
litis and corticosteroid injections. The Cochrane Controlled
Trial Register (1999, Issue 2) and Current Contents database
(July 1999) was searched using similar terminology. An
additional search for systematic reviews was carried out in
EMBASE and MEDLINE (Hunt and McKibbon, 1997).
Furthermore, a computer-aided search was carried out in
the trial register of the Cochrane field of ‘Rehabilitation
and Related Therapies’. Finally, references from retrieved
articles were screened (citation tracking).
2.2. Selection
For this systematic review we included studies that met
the following conditions:
1. Treatment regimens were allocated by a random proce-
dure (Schulz et al., 1994). The word “random” or “rando-
mised” should be mentioned;
2. Patients had a clinical diagnosis of lateral epicondylitis,
or lateral elbow pain increased by pressure on the lateral
epicondyle, and during resisted dorsiflexion of the wrist;
3. At least one of the treatments included one or more corti-
costeroid injections. Corticosteroid injection(s) had to be
contrasted with either no treatment, placebo, local anaes-
thetic, other corticosteroid injection or other conservative
treatments;
4. At least one clinically relevant outcome measure (pain,
global improvement, elbow specific functional status,
grip strength, or sick leave) was included;
5. Published as a full report before July 1999.
To determine whether a study should be included, the
abstracts of all identified hits were assessed by two
reviewers (D.A.W.M.W. and N.S.) independently. If there
was any doubt, the full article was retrieved, and then
blinded for author, journal and year of the trial by a research
assistant not involved in any other component of the
systematic review (S.K., see acknowledgement), and read
by both reviewers independently. Disagreements were
discussed and resolved in a consensus meeting.
2.3. Quality assessment
The Amsterdam-Maastricht consensus list (Van der Windt
et al., 1999; Van Tulder et al., 1997, 1999) was used for meth-
odological quality assessment, consisting of internal validity
criteria, descriptive criteria and statistical criteria (Table 1).
To determine the internal validity of the study, for each valid-
ity criterion the presence of sufficient information and the
likelihood of potential bias was evaluated. Each criterion
was rated positive, negative or inconclusive (insufficient
informationpresented).Equalweightswereapplied, resulting
in a total score for internal validity of each study, by summing
up the number of positive criteria (range 0–12), higher scores
indicating a lower likelihood of bias. In addition, we scored
the list of Jadad (Jadad et al., 1996) (See Table 1).
All articles eligible for the review were blinded for
authors, journal and year of publication (Jadad et al.,
1996). Included articles were independently assessed for
methodological quality by two blinded reviewers (N.S.
and W.J.J.A.). Overall disagreement was evaluated and
expressed as percentage of agreement and kappa statistics
(Cohen, 1960; Brennan and Silman, 1992). In a consensus
meeting disagreements were discussed and resolved. If
consensus could not be reached, a third reviewer
(D.A.W.M.W.) made the final decision. The two blinded
reviewers (N.S. and W.J.J.A.) independently extracted the
data regarding the interventions, timing of outcome assess-
ment, adverse effects, loss to follow-up and results. For
studies published in languages other than English, German
or Dutch, the help of a native speaker or translator with
content expertise was obtained (see acknowledgements).
2.4. Quantitative data synthesis
The results of each RCT were expressed as relative risks
(RR) with corresponding 95% confidence interval (95% CI)
for dichotomous data, a relative risk smaller than 1.0 indi-
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cating a beneficial effect of corticosteroid injections
(Mulrow and Oxman, 1997). RRs were considered clinically
relevant if RR was smaller than 0.7 or larger than 1.5, thus in
favour of the index or reference group, respectively. This
resembles an absolute difference of 25%. For continuous
data the standardised mean difference (SMD) was calcu-
lated: SMD ¼ ð0r 2 0tÞ=PSD, where 0r is mean improve-
ment in the reference group, 0t is mean improvement in
the treatment group, and PSD, pooled standard deviation
(Mulrow and Oxman, 1997), SMDs less than zero indicating
a beneficial effect in favour of corticosteroid injections. A
95% CI was computed for the SMD. The SMD was inter-
preted as described by Cohen (1988); i.e., a SMD of 0.2 was
considered to indicate a small beneficial effect, 0.5 a
medium effect, and 0.8 a large effect of corticosteroid injec-
tions. SMDs were considered to indicate a clinically rele-
vant effect if SMD was larger than 0.5.
2.5. Best evidence synthesis
Studies were weighted as to their internal validity, statis-
tical significance, clinical relevance, and power. Decision
rules to distinguish between ‘strong’, ‘weak’ and ‘insuffi-
cient’ evidence for the effectiveness of corticosteroid injec-
tions or for no differences in effect are presented in Fig. 1.
Statistically pooling (quantitative analysis) using random
effects model, was conducted on the following conditions:
Firstly, studies had acceptable internal validity scores
(Moher et al., 1998; Schultz et al., 1995) (cut-off point for
acceptable internal validity was 7 or more (.50% of total
score)); secondly, studies were clinically homogenous, and
finally, statistical homogeneity (Chi square test; P . 0:05)
between studies results existed. Clinically homogeneity
between studies existed, if studies were comparable to the
timing of outcome assessment: short-term (#6 weeks), inter-
mediate-term (6 weeks–6 months), and long-term up ($6
months) follow-up, control group (no treatment, placebo
injection, injection with local anaesthetic, other corticoster-
oid injection, and other conservative treatment), and outcome
measure (e.g. pain, global improvement, grip strength).
If a quantitative analysis of data was not possible, conclu-
sions regarding the strength of evidence were based on the
consistency of findings between individual studies (qualita-
tive analysis). Results were considered consistent if more
than 75% of the studies reported similar results on the same
outcome measure (i.e. favouring the same intervention) (Van
der Windt et al., 1999; Van Tulder et al., 1999). In case,
statistical pooling was only possible for less than 75% of
the studies, an additional qualitative analysis was performed.
If different conclusions were found between quantitative and
qualitative analysis, conclusions were based on the analysis
with the strongest evidence (see Fig.1).
3. Results
3.1. Study selection
The results of our search strategy are presented in Fig. 2.
Reviewing 248 abstracts and 29 full papers, resulted in
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Table 1
Criteria for the methodological assessment of randomised clinical trialsa
Validity criteria
V1 Adequate randomisation: adequate procedure for generation of a random number sequence
V2 Concealed randomisation
V3 Baseline similarity of intervention groups
V4 Control for co-interventions in design
V5 Co-interventions reported for each group separately
V6 Adherence to interventions: .70% in intervention groups(s), with exception of waiting list or no treatment group
V7 Care provider blinded
V8 Patient blinded
V9 Withdrawals and drop-outs: #20% for short term follow-up, and #30% for intermediate term and long term follow-up and no
substantial bias (numerical inequality between groups or differences in reasons for withdrawal/drop-out)
V10 Identical timing of outcome assessment
V11 Intention-to-treat analysis
V12 Outcome assessor blinded
Descriptive criteria
D1 Specification of eligibility criteria
D2 Baseline characteristics described
D3 Description of interventions
D4 Adverse effects described and attributed to allocated treatment, or explicit report of ‘no adverse effects’
D5 Short term follow-up (#6 weeks)
D6 Intermediate term follow-up (6 weeks–6 months)
D7 Long term follow-up ($6 months)
Statistical criteria
S1 Presentation of sample size at randomisation and at follow-up
S2 Presentation of point estimates and distribution measures
a Operationalisation of the criteria is presented in Appendix A.
inclusion of 12 articles (Bär et al., 1997; Day et al., 1978;
Erturk et al., 1997; Freeland and Gribble, 1954; Haker and
Lundeberg, 1993; Halle, 1986; Hay et al., 1999; Murley and
Lond, 1954; Oksenberg et al., 1998; Price et al., 1991; Saar-
tok and Eriksson, 1986; Verhaar et al., 1996). Screening the
references of all retrieved RCTs and reviews resulted in one
additionally eligible RCT (Baily and Brock, 1957).
3.2. Study characteristics
Details regarding the selection criteria, interventions and
outcome measures of all included studies are presented in
Appendix B.
In almost half of the studies, the duration of the elbow
complaints at randomisation was not specified (Baily and
Brock, 1957; Freeland and Gribble, 1954; Halle, 1986;
Murley and Lond, 1954; Oksenberg et al., 1998; Saartok
and Eriksson, 1986). All other studies included a mixed
population of patients with acute, subacute and chronic
lateral epicondylitis (Bär et al., 1997; Day et al., 1978;
Erturk et al., 1997; Haker and Lundeberg, 1993; Hay et
al., 1999; Price et al., 1991; Verhaar et al., 1996).
One study (Haker and Lundeberg, 1993) explicitly
excluded patients with concomitant neck and/or shoulder
complaints, and ten studies (Bär et al., 1997; Day et al.,
1978; Erturk et al., 1997; Freeland and Gribble, 1954;
Halle, 1986; Hay et al., 1999; Murley and Lond, 1954;
Oksenberg et al., 1998; Price et al., 1991; Saartok and Eriks-
son, 1986) did not specify whether patients had concomitant
neck or shoulder complaints.
3.3. Quality assessment
The inter-rater agreement on the internal validity items
was good (overall agreement 83% (120/144), kappa statistic
0.62). In a consensus meeting, all disagreements were
discussed and resolved. Most disagreements were caused
by differences in interpretation of adherence to the interven-
tion (V6) and withdrawals and drop-outs (V9).
In general, the scores for internal validity were low (mean
(SD) 3.9 (2.0)). Only one study had an acceptable internal
validity score ($7 points) (Hay et al., 1999). The most
prevalent flaws were associated with inadequate control
and reporting of co-interventions (V4,V5) and blinding of
care provider (V7). Most studies lacked sufficient informa-
tion on the randomisation procedure (V1, V2), baseline
similarity (V3), number of withdrawal and drop-outs (V9)
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Fig. 1. Best-evidence synthesis.
and analysis (V11), making it impossible to determine the
likelihood of bias.
3.4. Effectiveness of corticosteroid injections
According to our best-evidence synthesis, there is insuffi-
cient evidence to either support or refute the effectiveness of
corticosteroid injections compared with placebo, local
anaesthetic or other conservative treatments, due to low
internal validity scores of nearly all studies. Only one
study had an acceptable internal validity score (Hay et al.,
1999). As we prefer not to ignore the results of the other
available studies, we have carried out a sensitivity analysis,
including all available studies.
3.5. Short-term results
Table 2 shows the short-term effects (#6 weeks) of corti-
costeroid injections on pain, global improvement and grip
strength. Except of one study (Saartok and Eriksson, 1986),
all studies who measured and sufficiently reported either
pain or global improvement found statistically significant
and clinically relevant short-term results in favour of corti-
costeroid injections.
3.6. Corticosteroid injection compared to placebo injection
Only two studies compared the effects of corticosteroid
injection to those of a saline injection (Day et al., 1978;
Saartok and Eriksson, 1986). One study (Day et al., 1978)
found statistically significant and clinically relevant results
in favour of corticosteroid injections. A quantitative analy-
sis for global improvement was not possible, because of
statistical heterogeneity. For global improvement, the treat-
ment results of the individual studies were inconsistent. Pain
and grip strength was measured by only one study (Saartok
and Eriksson, 1986). Therefore, according to the best
evidence synthesis, there is insufficient evidence to support
or refute the effectiveness of corticosteroid injection
compared to placebo injection.
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Short-term results: summary of validity scores, sample size and effect sizesa (95% confidence interval) for pain, global measure of improvement and grip strength
Interventionb (index group vs reference group) Validity scorec Oxford scored Sample sizee Short term outcome assessment (#6 weeks)
Pain Global improvement Grip strength
Weeks SMD (95% CI) RR (95% CI) SMD (95% CI)
Placebo treatment
Corticosteroid injection vs placebo
Day (1 ml MP-acetate vs 1 ml saline 0.9%) 2 1 29 Unclear NM 0.11 (0.04, 0.33) NM
Saartok (1 ml BM 1 0.5 ml Prilocaine 1 placebo tablets vs Naproxen 250
mg 1 1.5 ml saline injection)
2 1 10 2 0.04 (20.82, 0.90) 1.21 (0.65, 2.26) 0.19 (20.67, 1.05)
Local anaesthetic
Corticosteroid injection 1 local anaesthetic vs local anaesthetic
Price1 (2 ml HC 25 mg 1 lignocaine 1% vs 2 ml lignocaine 1%) 6 3 29 4 20.62 (21.15, 20.10) NM 20.37 (20.89, 0.15)
Price1 (2 ml TC 10 mg 1 lignocaine 1% vs 2 ml lignocaine 1%) 6 3 29 4 21.04 (21.59, 20.50) NM 20.43 (20.95, 0.09)
Corticosteroid injection vs local anaesthetic
Murley (1 ml HC-acetate 25 mg vs 1 ml procaine 2%) 4 1 18 4 NM 0.32 (0.10, 0.98) NM
Day (1 ml MP-acetate vs 1 ml xylocaine 1%) 2 1 35 Unclear NM 0.10 (0.03, 0.31) NM
Conservative treatments
Corticosteroid injection vs elbow support
Haker (0.2 ml TC-acetonide 10 mg/ml 1 0.3 ml BHC vs elbowband) 3 1 18 2 NM 0.36 (0.18, 0.71) NA
Haker (0.2 ml TC-acetonide 10 mg/ml 1 0.3 ml BHC vs splintage) 3 1 18 2 NM 0.33 (0.17, 0.65) NA
Erturk (20 mg TC 1 0.5 ml lidocaine 2% vs epicondylitis bandage) 1 1 8 3 NA NM NA
Corticosteroid injection vs elbow support 1 NSAID
Erturk (20 mg TC-acetate 1 0.5 ml lidocaine 2% vs acemetacin 90 mg
daily 1 epicondylitis bandage)
1 1 9 3 NA NM NA
Corticosteroid injection 1 elbow support vs elbow support
Erturk (20 mg TC-acetate 1 0.5 ml lidocaine 2% 1 epicondylitis bandage
vs epicondylitis bandage)
1 1 8 3 NA NM 21.01 (21.99, 20.02)
Corticosteroid injection vs NSAID
Hay (MP 20 mg 1 0.5 ml lignocaine 1% vs Naproxen 500 mg 2 daily 2
weeks)
8 3 53 4 0.57** (0.43, 0.76) 0.62 (0.49, 0.79) 0.67** (0.54, 0.84)
Corticosteroid injection vs physiotherapy
Verhaar (1 ml TC-acetate 1% 1 1 ml Lidocaine 1% vs friction
massage 1 Mills’ manipulation)
5 3 53 6 0.61** (0.48, 0.78) 0.45 (0.29, 0.69) 20.65 (21.04, 20.25)
Halle (HC 1 lidocaine vs transcutaneous electrical nerve stimulation) 3 1 12 1 NA NA NM
a Values are the effect sizes (95% confidence intervals) for each outcome measure; standardised mean differences (SMD) for continuous outcome measures and relative risks (RR) for dichotomous outcome
measures. SMD ,0 in favour of corticosteroid injections (index group); RR ,1 in favour of corticosteroid injections (index group); NM, not measured; NA, not able to calculate effect sizes due to insufficient
data presentation.
b MP, methylprednisolone; BM, betamethasone; HC, hydrocortisone; TC, triamcinolone; BHC, bupivacaine hydrochloride.
c Validity score: range 0–12; 12 least risk of bias.
d Oxford score according list of Jadad (range 0–5).
e Smallest group.
**Analysed as dichotomous data (RR).
3.7. Corticosteroid injection compared to injection with
local anaesthetic
Three studies compared the effects of corticosteroid
injection to a local anaesthetic (Price et al., 1991; Murley
and Lond, 1954; Day et al., 1978). All three studies found
statistically significant and clinically relevant results in
favour of corticosteroid injections on one or more outcome
measures. Quantitative analysis showed that the pooled esti-
mate for global improvement was statistically significant
and clinically relevant (RR (95%CI): 0.18 (0.08, 0.39).
Based on the adjusted best evidence synthesis (sensitivity
analysis) there is strong evidence for the effectiveness of
corticosteroid injections on global improvement compared
to an injection with local anaesthetic. As only one study
measured pain and grip strength, there is insufficient
evidence for these outcome measures.
3.8. Corticosteroid injection compared to conservative
treatment
Five studies compared corticosteroid injections with
another conservative treatment (elbow support (Haker and
Lundeberg, 1993; Erturk et al., 1997), non-steroidal anti-
inflammatory drugs (Hay et al., 1999), physiotherapy
(Verhaar et al., 1996; Halle, 1986). The quantitative analysis
showed that the pooled estimate for pain was statistically
significant and clinically relevant (RR (95%CI): 0.60 (0.50,
0.72). Due to the low number of studies (two out of four)
that sufficiently reported data on pain, the best evidence
synthesis resulted in weak evidence for the effectiveness
of corticosteroid injections compared to other conservative
treatments.
Global improvement was assessed in four studies (Halle,
1986; Haker and Lundeberg, 1993; Hay et al., 1999;
Verhaar et al., 1996). Quantitative analysis for global
improvement showed that the pooled estimate was statisti-
cally significant and clinically relevant (RR (95%CI): 0.50
(0.36, 0.70) in favour of corticosteroid injections (strong
evidence).
Due to insufficiently presented data and differences in
grip strength outcomes (continuous versus dichotomous),
quantitative analyses was only possible for two studies
(50%) (Erturk et al., 1997; Verhaar et al., 1996). The
pooled estimate was statistically significant and clinically
relevant (SMD (95%CI): 20.70 (21.07, 20.33) in favour
of injections. The additional qualitative analysis for grip
strength showed that 75% of the studies showed statisti-
cally significant and clinically relevant results (strong
evidence).
3.9. Intermediate and long term effectiveness
Only six studies performed an intermediate (6 weeks–6
months) or long-term ($6 months) outcome assessment
(Freeland and Gribble, 1954; Price et al., 1991; Baily and
Brock, 1957; Haker and Lundeberg, 1993; Hay et al., 1999;
Verhaar et al., 1996). The results are presented in Table 3.
None of the studies found statistically significant results in
favour of corticosteroid injections. In contrast, the only
study reporting significant differences (Hay et al., 1999)
found statistically significant and clinically relevant results
for some outcome measures in favour of non-steroidal anti-
inflammatory drugs at 6 months of follow-up.
3.10. Effectiveness of different amount, doses and
suspensions of corticosteroid injections
Four studies (Bär et al., 1997; Oksenberg et al., 1998;
Price et al., 1991 (Price 1 and Price 2) compared different
amount, dosages, and suspensions of corticosteroids. Only
one study (Oksenberg et al., 1998) found for pain a clini-
cally relevant difference in favour of betamethasone-fosfaat
compared to betamethasone-acetate, although this was not
statistically significant (SMD: 20.86 (22.00, 0.28). Statis-
tical pooling of treatment effects was not sensible because
nearly each study evaluated a different suspension of corti-
costeroid. Thus, there is insufficient evidence for the use of
any specific amount, dosage or type of corticosteroid
suspension.
3.11. Adverse effects
Eight studies provided information on the adverse effects
of corticosteroid injections, such as facial flushes, post
injection pain and local skin atrophy (Bär et al., 1997;
Baily and Brock, 1957; Haker and Lundeberg, 1993; Hay
et al., 1999; Saartok and Eriksson, 1986; Price et al., 1991;
Murley and Lond, 1954; Verhaar et al., 1996). Post injection
pain (11–58%) and local skin atrophy (17–40%) was
reported in four studies, but irrespectively whether patients
had received a corticosteroid injection, or control treatment
(Price et al., 1991; Haker and Lundeberg, 1993; Hay et al.,
1999; Saartok and Eriksson, 1986). Occurrence of facial
flushes as side-effect of corticosteroid injections was
mentioned by only one study (Bär et al., 1997).
4. Discussion
Based on our best evidence synthesis, weighing 13
studies with respect to their internal validity, power, and
treatment results, we should conclude that there is insuffi-
cient evidence to draw firm conclusions on the overall effec-
tiveness of corticosteroid injections for lateral epicondylitis.
This is caused by the low internal validity scores assigned to
almost all studies. However, four of the twelve internal
validity items were in nearly all studies insufficiently
described. Therefore, we decided to perform an sensitivity
analysis, including all available studies irrespective of their
internal validity scores.
Almost all studies report beneficial short-term effects,
which were statistically significant and clinically relevant
on nearly all outcome measures in favour of corticosteroid





























Intermediate and long term results: summary of validity scores, sample size and effect sizesa (95% confidence interval) for pain, global measure of improvement and grip strength
Interventionb (index group vs reference group) Validity scorec Oxford scored Sample sizee Intermediate and long term outcome assessment (. 6 weeks)
Pain Global improvement Grip strength
Weeks SMD (95% CI) RR (95% CI) SMD (95% CI)
Local anaesthetic
Corticosteroid injection vs local anaesthetic
Freeland (1 ml HC 25 mg vs 1 ml procaine 5%) 2 2 7 9–17 NM 0.97 (0.41, 2.32) NM
Corticosteroid injection 1 local anaesthetic vs local anaesthetic
Price1 (2 ml HC 25 mg 1 lignocaine 1% vs 2 ml lignocaine 1%) 6 3 29 8 20.15 (20.69, 0.38) NM 20.16 (20.69, 0.38)
24 0.53 (20.03, 1.09) 20.16 (20.71, 0.39)
Price1 (2 ml TC 10 mg 1 lignocaine 1% vs 2 ml lignocaine 1%) 6 3 29 8 20.48, (21.02, 0.06) NM 20.31 (20.85, 0.22)
24 0.39 (20.16, 0.94) 0.22 (20.32, 0.77)
Baily (1 ml HC 25 mg 1 1-3 ml procaine 2% followed by Mills’
manipulation vs 1–3 ml procaine 2% followed by Mills’
manipulation)
4 1 20 9 NM 0.67 (0.40, 1.11) NM
Conservative treatments
Corticosteroid injection vs elbow support
Haker (0.2 ml TC 10 mg/ml 1 0.3 ml BHC vs elbowband) 3 1 18 13 NM 0.76 (0.32, 1.80) NA
26 1.83 (0.58, 5.77)
52 0.92 (0.27, 3.07)
Haker (0.2 ml TC 10 mg/ml 1 0.3 ml BHC vs splintage) 3 1 18 13 NM 0.52 (0.24, 1.16) NA
26 3.00 (0.73, 12.27)
52 1.22 (0.32, 4.65)
Corticosteroid injection vs NSAIDs
Hay (MP 20 mg 1 0.5 ml lignocaine 1% vs Naproxen 500 mg 2 £ daily
2 weeks)
8 3 53 26 1.71** (1.17, 2.51) NM 0.98** (0.78, 1.22)
52 1.33** (0.83, 2.15) 1.24** (0.91, 1.69)
Corticosteroid injection vs physiotherapy
Verhaar (1 ml TC 1% 1 1 ml lidocaine 1% vs friction
massage 1 Mills’ manipulation)
5 3 53 52 1.20** (0.96, 1.51) 1.24 (0.81, 1.90) 20.27 (20.66, 0.12)
a Values are the effect sizes (95% confidence intervals) for each outcome measure; standardised mean differences (SMD) for continuous outcome measures and relative risks (RR) for dichotomous outcome
measures. SMD , 0 in favour of corticosteroid injections (index group); RR , 1 in favour of corticosteroid injections (index group); NM, not measured; NA, not able to calculate effect sizes due to insufficient
data presentation.
b MP, methylprednisolone; HC, hydrocortisone; TC, triamcinolone; BHC, bupivacaine hydrochloride.
c Validity score: range 0–12; 12 least risk of bias.
d Oxford score according list of Jadad (range 0–5).
e Smallest group.
**Analysed as dichotomous data (RR).
injections. These beneficial short-term effects, including
diminished pain and increased grip strength, were not
found at intermediate or long-term follow-up. By contrast,
when comparing corticosteroid injections with another
conservative treatment, there is a suggestion of more
favourable outcomes at long-term follow-up for medication
or physiotherapy (Hay et al., 1999; Verhaar et al., 1996).
4.1. Review methodology
Several aspects of our review methodology are open to
discussion. Firstly, although several different databases
were used to identify relevant articles, it is possible that
we failed to detect relevant publications. We attempted to
evaluate the influence of potential publication bias by
making a funnel plot (Sutton et al., 2000), plotting the
RRs against the sample size of each study. The plot showed
a symmetric distribution of studies (data not shown).
Furthermore, our comprehensive search had been
completed in July 1999. However, an additional search in
Medline over the last 2 years did not reveal any additional
publications.
Secondly, the conclusions of our review depend on
certain decision rules regarding quality assessment and the
cut-off points used in our best-evidence synthesis. These
decisions are arbitrary, and may of influence on the outcome
of a systematic review. Jüni et al. (1999), for example, have
shown that the use of different methods for quality appraisal
may lead to different conclusions regarding the effective-
ness of treatment, based on the same set of trials. We feel
that an assessment of methodological quality is an important
aspect of systematic reviews, but decided to carry out a
sensitivity analysis in which the quality of methods was
not considered. The results of this analysis were consistent,
irrespective of the validity scores: positive short-term
results and negative intermediate- and long-term results.
However, we still feel more high-quality studies are neces-
sary.
4.2. Implications for research
Our updated and more extensive review confirms the
conclusions by Assendelft et al. (1996), regarding the poten-
tially beneficial outcome of corticosteroid injections within
6 weeks of follow-up. Both reviews stress the poor validity
of most studies, although four new recent RCTs were
included in our review (Hay et al., 1999; Oksenberg et al.,
1998; Bär et al., 1997; Erturk et al., 1997). This again
emphasizes the need for good quality RCTs of sufficient
size, investigating the short, intermediate, and long-term
effects of corticosteroid injections for lateral epicondylitis
with standardised outcome measures. The items of our
checklist provide good guidance for the design of such
studies. More research is also clearly needed to investigate
the late possible adverse outcomes of corticosteroid injec-
tions at long-term follow-up compared to other conservative
treatments (Hay et al., 1999; Verhaar et al., 1996).
In conclusion, corticosteroid injections seem to be effec-
tive in the short-term. Additional well-designed trials with
long-term follow-up are needed to provide evidence on the
beneficial and adverse long-term effects of corticosteroid
injections.
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Appendix A
Specification of the criteria from Table 1. Each criterion
must be applied independently of the other criteria.
In general: ‘NO’ Bias was considered to be likely.
Don’t know: Insufficient information is given, the criter-
ion is rated as inconclusive.
‘YES’: Sufficient information is available and bias is
considered to be unlikely
V1. A random (unpredictable) assignment sequence (e.g.
numbered, opaque sealed envelopes). Methods of allocation
using date of birth, date of admission, hospital numbers, or
alternation are not regarded as appropriate (No). If the word
‘random’ or ‘randomised’ is mentioned the answer is ‘Don’t
know’.
V2. Assignment generated by an independent person not
responsible for determining eligibility of the patients. This
person has no information about the persons included in the
trial and has no influence on the assignment sequence or the
decision about eligibility of the patient.
V3. In order to receive a ‘yes’ groups have to be similar
regarding four of the most important prognostic factors: age,
duration of complaints, concomitant neck and shoulder
complaints and baseline main outcome measure(s). If a
baseline difference exists in one of these factors, a ‘no’
applies.
V4. Co-interventions concerning other physical therapy
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modalities, oral medication or injections are either standar-
dised or avoided in trial design.
V5. A report on co-interventions for each group sepa-
rately.
V6. The reviewer determines whether the adherence to
the interventions is acceptable, based on the reported inten-
sity, duration, number and frequency of sessions for both the
index intervention and control intervention(s). Arbitrarily
an adherence .70% in index group(s) and in placebo-
controlled trials also in control group(s) is considered to
be sufficient.
V7. The reviewer determines if enough information about
the blinding is given in order to score a yes’. For exercise
therapy this item always scores a ‘no’.
V8. The reviewer determines when enough information
about the blinding is given in order to score a ‘yes’. For
exercise therapy and ‘hands-on’ therapy, like massage or
manipulation, this item always scores a ‘no’.
V9. Participants who were included in the study but did
not complete the observation period or were not included in
the analysis must be described. If the percentage of with-
drawals and dropouts does not exceed 20% for short-term
follow-up and 30% for intermediary-term and long-term
follow-up and does not lead to substantial bias a ‘yes’ is
scored. No report of dropouts scores as ‘don’t know’.
V10. Timing of outcome assessment identical for all
intervention groups; for all important outcome assessments.
V11. All randomised patients are reported/analysed for
the most important moments of effect measurement (minus
missing values) irrespective of non-compliance and co-
interventions.
V12. The reviewer determines when enough information
about blinding is given to score a ‘yes’.
D1. In order to score a ‘yes’ explicit classification criteria
for lateral epicondylitis should be described.
D2. In order to receive a ‘yes’ groups have to be described
regarding four of the most important prognostic factors: age,
duration of complaints, neck and shoulder complaints and
baseline main outcome measure(s).
D3. Adequate description of type, modality, application
technique, intensity, duration, frequency of sessions for both
the index intervention and control intervention(s) in order to
be able to replicate the study.
D4. Each event described and correctly attributed to allo-
cated treatment; if explicit report of ‘no adverse effects’, a
‘yes’ applies. Scores either a ‘yes’ or a ‘no’, a ‘don’t know’
doesn’t exist.
D5. Outcome assessment #6 weeks after randomisation.
D6. Outcome assessment .6 weeks and ,6 months after
randomisation.
D7. Outcome assessment $6 months after randomisation.
S1. To be presented per group at randomisation, for main
outcome assessment and for separate short, intermediate and
long-term follow-up moments.
S2. For all of the important outcome measures (pain,
global improvement, elbow specific functional status) both
point estimates and measures of variability should be
presented separately. Point estimates are: means, medians,
modes, etc.; Measures of variability are: standard devia-
tions, 95% confidence intervals, etc. For dichotomous or
categorical data proportions have to be presented or enough
data presented to be calculated.




























Appendix B.: Characteristics of included studies (alphabetical order)
Study characteristics










assessment at 2, 7 and 21
days after randomisation.
Drop-outs: i, six patients
(5%); ii, eight patients (7%)
at 21 days after
randomisation.
246 patients with epicondylitis humeri
radialis. Mean age (sd): 48.5 years (12.0),
women: 129 (52%). Duration of elbow
complaints: 135 (55%) acute, 111 (45%)
chronic. Inclusion criteria: pain by
pressure on lateral epicondyl, pain at
lateral epicondyl for at most 7 days, pain
by resisted elbow flexion. Exclusion
criteria: not described.
i, Injection with 1.5 ml
dexamethason-21-palmitate
(n ¼ 123). ii, Injection with 1 ml
dexametason-21-acetaat (n ¼ 123).
Co-interventions: not reported
Adverse effects: i, Warm sensation
at the elbow (n ¼ 1), slight
haemorrhage (n ¼ 1); ii, facial flush
(n ¼ 3), red coloured elbow
(n ¼ 1), skin irritation of the
shoulder (n ¼ 1), inflammation of
the bladder (n ¼ 1).
Results at 2 days: (a) pain by pressure on lateral epicondyl (5 point scale): i, 15/
123; ii, 17/123 very painful; (b) pain by resisted elbow flexion (5 point scale): i,
12/123; ii, 13/123, (c) patient satisfaction: i, 72% (89/123); ii, 68% (84/123)
much improved/completely recovered; (d) severity of the elbow complaints
according to the care provider: i, 71% (87/123); ii, 67% (82/123) much
improved/completely recovered. Results at 1 week: (a) pain by pressure on
lateral epicondyl (5 point scale): i, 14/123; ii, 12/123 very painful; (b) pain by
resisted elbow flexion (5 point scale): i, 10/123; ii, 9/123 (c) patient
satisfaction: i, 74% (91/123); ii, 69% (85/123) much improved/ completely
recovered; (d) severity of the elbow complaints according to the care provider:
i, 74% (91/123); ii, 70% (86/123) much improved/ completely recovered.
Results at 3 weeks: (a) pain by pressure on lateral epicondyl (5 point scale): i,
17/117; ii, 12/115 very painful; (b) pain by resisted elbow flexion (5 point
scale): i, 11/117; ii, 10/115; (c) patient satisfaction: i, 74% (87/117); ii, 72%
(83/115) much improved/ completely recovered, (d) severity of the elbow


















assessment at 2 months after
randomisation. Drop-outs:
nine patients because of
non-attendance (group
unclear).
40 patients with tennis elbow in secondary
care. Mean age: 45.5 years, women: 26
(65%). In- and exclusion criteria: not
reported
i, Injection with 1 ml
hydrocortisone acetate (25
mg) 1 1–3 ml procaine 2%
followed by Mill’s manipulation
(n ¼ 20). ii, Injection with 1–3 ml
procaine 2% followed by Mill’s
manipulation (n ¼ 20) Co-
interventions: unclear (where
symptoms were unchanged after 3
weeks a course of physiotherapy
was instituted and in eight cases
still unrelieved after 2 months a
second injection of hydrocortisone
was given) Adverse effects: i,
exacerbation of symptoms for 48 h
(n ¼ 5), ii, exacerbation of
symptoms for 48 h (n ¼ 5).
Results after 9 weeks: (a) global measure of improvement (4 point scale): i, 10/
20; ii, 5/20 relieved of all symptoms. In addition, the results were analysed in
relation to age, history of trauma, length of history, the presence of associated
symptoms in the neck and shoulder, and presence or absence of previous
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not blinded for intervention.
No information on blinding
patient. Outcome
assessment: fortnightly until
the patients were either
relieved of symptoms or
changed to another therapy
owing to failure. Minimum
follow-up period of 1 year
and a maximum of 4 years.
No information on drop-
outs.
95 patients (100 tennis elbows) with tennis
elbow in secondary care. Range age: 17–
72, women: 49 (52%), duration of elbow
complaints: 10% (,1 month), 56% (1–3
months), 18% (4–6 months), 10% (7–12
months), 6% (. 12 months). Inclusion
criteria: tenderness at the lateral epicondyl
and the presence of Mill’s sign (pain at the
site of tenderness when the elbow is
extended with the forearm fully pronated
and the wrist fully flexed). Exclusion
criteria: not reported.
i, Injection with 1 ml
methylprednisolone acetate
(n ¼ 36). ii, Injection with 1 ml
xylocaine 1% (n ¼ 35). iii,
Injection with 1 ml saline 0.9%
(n ¼ 29). No information on co-
interventions and adverse effects.
Results after one or two injections (timing of outcome assessment is unclear):
(a) Global measure of improvement (4-point scale: cured, very much
improved, only slow improvement, worse): i, 33/36 elbows; ii, 7/35; iii, 7/29







Randomly split in four
groups. Patient and care




assessment at 3 weeks after
randomisation. No
information on drop-outs.
36 patients with lateral epicondylitis in
secondary care. Mean age (range): 47.6
years (36–66), women: 25 (69%), mean
duration of elbow complaints (range): 17.7
weeks (3–156). Inclusion criteria: history
of pain on gripping and tenderness over the
lateral epicondyle. Exclusion criteria:
history of systemic diseases (like diabetes
mellitus, chronic renal insufficiency etc.),
recurrence in the last year, treatment
period for present complaints.
i, Local injection with 20 mg
triamcinolone acetate combined
with 0.5 ml 2% lidocaine (n ¼ 9). ii,
Local injection with 20 mg
triamcinolone acetate combined
with 0.5 ml 2%
lidocaine 1 epicondylitis bandage
(n ¼ 10). iii, Epicondylitis bandage
(n ¼ 8). iv, NSAID (acemetacin 90
mg/daily in a single
dose) 1 epicondylitis bandage
(n ¼ 9). No information on co-
interventions and adverse effects.
Baseline results: (a) mean (range) pain at rest (VAS): i, 12.44 (0–52); ii, 10.30
(0–34); iii, 12.88 (0–41); iv; 17.89 (0–45); (b) mean (range) pain during
resistive wrist extension (VAS): i, 47.0 (17–76); ii, 43.70 (16–79); iii, 59.63
(42–80); iv. 38.33 (5–75); (c) mean (range) tenderness over the lateral
epicondyle (0–3): i, 1.89 (1–3); ii, 2.10 (1–3); iii, 2.38 (2–3); iv, 2.00 (1–3); (d)
mean (range) grip strength (kg): i, 18.52 (7.6–30); ii, 17.85 (11.3–26.3); iii,
15.35 (9.6–21.6); iv, 18.20 (7.3–30). Results after 3 weeks: Mean improvement
(a) pain at rest (VAS): i, 7.67; ii, 10.30; iii, 5.13; iv, 10.78; (b) pain during
resistive wrist extension (VAS): i, 27.11; ii, 40.90; iii, 13.62; iv, 12.56; iii vs iv.
P , 0.05, ii vs iii P , 0.05; (c) tenderness over de lateral epicondyle (0–3): i,
1.22; ii, 1.20; iii, 0.63; iv; 0.89; (d) grip strength (kg): i, 3.66; ii, 5.40; iii, 0.42;




















assessment at 2–4 days, 1
week, 3 weeks and monthly.
No information on drop-
outs.
14 patients (16 elbows) with tennis elbow.
No information on age, gender and
duration of complaints. Inclusion criteria:
(1) tenderness over the anterior aspect of
the lateral epicondyle, (2) pain in the
extensor origin, radiating down the arm on
gripping and on resisted extension of the
wrist, and (3) full range of passive
movements of the elbow. Exclusion
criteria: If the tenderness or pain were
classified as ‘none’ or ‘slight’.
i, Local injection of 1 ml
hydrocortisone 25 mg (n ¼ 9). ii,
Local injection of 1 ml procaine 5%
(n ¼ 7). No information on co-
interventions and adverse effects.
Results at 9–17 weeks: (a) Global measure of improvement (4 point scale): i, 4/







































not described. Patient and




assessment at 2 weeks, 3, 6
and 12 months. Drop-outs:
ii, One patient (5%) after 2
weeks, i, one; ii, two; iii,
eight patients after 3
months: i, nine; ii; seven; iii;
seven patients. After 6
months. i, ten; ii, seven; iii,
eight patients after 1 year.
61 patients with lateral epicondylalgia in
secondary care. Mean age (range): 47.9
(26.8–75.8), women: 19 (34%), median
duration of elbow complaints (range): 5
months (1–36). Inclusion criteria: pain
duration of 1 month and a record of pain
over the lateral epicondyl during two or
more of the four following clinical tests:
(1) palpation of the lateral epicondyl, (2)
resisted wrist extension, (3) passive
stretching of the extensor muscle group,
(4) resisted finger extension. Exclusion
criteria: dysfunction in the shoulder, neck
and/or thoracic region; local arthritis or
generalised polyarthritis; neurological
abnormality, radial nerve entrapment.
i, Local injection of 0.3 ml
bupivacaine hydrochloride and 0.2
ml triamcinolone acetonide 10 mg/
ml. If no effect was observed within
1 week a second injection was
given (n ¼ 19). ii, Elbow-band
group (n ¼ 18). iii, Splintage group
(n ¼ 19). Instruction all groups: use
the arm but avoid painful
movements. Instructions for group
ii and iii: use support daily during
activity for 3 months. Co-
interventions: none. Adverse
effects: i, two patients (11%)
worsening of pain after injection.
Baseline results: (a) median vigorimeter test (Kpa): i, 24; ii, 39; iii, 20. Results
after 2 weeks: (a) Median improvement on vigorimeter: i, 28; ii, 2; iii, 3. (b)
Global measure of improvement (5 point-scale): i, 13/19; ii, 2/17; iii, 1/19
excellent or good results. Results after 13 weeks: (a) Median improvement on
vigorimeter: i, 33; ii, 10; iii, 20; (b) Global measure of improvement (5 point-
scale): i, 12/18; ii, 9/16; iii, 4/11 excellent or good results. Results after 26
weeks: (a) Median improvement on vigorimeter: i, 26; ii, 36; iii, 38. (b) Global
measure of improvement (5 point-scale): i, 5/10; ii, 8/11; iii, 10/12 excellent or
good results. Results after 52 weeks: (a) Median improvement on vigorimeter:
i, 40; ii, 48; iii, 42; (b) Global measure of improvement (5 point-scale): i, 6/9;









reported at long term
follow-up.
Halle (1986) Randomisation: table of
random numbers. Care
provider, patient outcome
assessor not blinded for
intervention. Outcome
assessment after 5 days. No
information on drop-outs.
48 patients with lateral epicondylitis in
primary care: Army Medical Department.
Range age: 20–59 years; women 26 (54%)
for all patients. Inclusion criteria:
Localised pain over the common extensor
tendon origin with resisted wrist extension
and point tenderness over the lateral
epicondyle. Exclusion criteria: positive
neurological examination.
i, Ultrasound using conventional
coupling medium 20 min, daily,
five treatments (n ¼ 12). ii,
Ultrasound with 10% hydro-
cortisone coupling; 20 min, daily;
five treatments (n ¼ 12). iii,
Transcutaneous electrical nerve
stimulation, 20 min; daily, five
treatments (n ¼ 12). iv,
Subcutaneous injection with
hydrocortisone and lidocaine
(n ¼ 12). Standardised home
programme: tennis elbow cuff,
avoiding strenuous activity, ice
massages daily. No information on
adverse effects.





































number table (blocks of six).
Patient and care-provider
not blinded for intervention.
Outcome assessor blinded
for intervention. Outcome
assessment at 4 weeks, 6
months and 12 months.
Drop-outs: iii, one patient
after 12 months follow-up.
164 patients with lateral epicondylitis of
elbow in primary care. Range age: 18–70
years, women: 78 (48%), duration of
elbow complaints: 50 patients (30%) . 3
months. Inclusion criteria: pain and
tenderness in the lateral region of the
elbow; no consultation with symptoms in
the same elbow during the preceding 12
months; age 18–70 years. Exclusion
criteria: history of inflammatory arthritis or
gross structural abnormality of the elbow;
contraindications to non-steroidal anti-
inflammatories or local steroid injection;
pregnancy or breast feeding.
i, Local corticosteroid injection of
methylprednisolone 20 mg 1 0.5
ml lignocaine 1% (n ¼ 53). ii,
Naproxen 500 mg twice daily for 2
weeks (n ¼ 53). iii, Placebo tablets
twice daily for 2 weeks (n ¼ 58).
Standard advice was given to take
the drug with food and about
potential side effects for groups ii
and iii, All participants were
provided with co-codamol for
additional pain relief and an
information leaflet about ‘tennis
elbow’. Co-interventions: i, six
(12%); ii, nine (18%); ten (19%)
patients received co-interventions
at 4 weeks; i, 17 (35%), 19 (38%),
19 (37%) patients received co-
interventions during 12 months
follow-up. Adverse effects: i, post
injection pain (number of patients
unknown); ii, four patients
gastrointestinal side effects, one
patient allergic reaction (oedema)
Local skin atrophy at the lateral
epicondyle at 6 and 12 months:
three patients (ii and iii group).
Baseline results: (a) Elbow pain today: i, 50/53; ii, 51/53; iii, 57/58, (b) Pain
every day for 1 week: i, 50/53; ii, 47/53; iii, 50/58, (c) pain free grip strength .
300 mm Hg (average of two readings with hand held dynamometer): i, 3/53; ii,
1/53; iii, 1/58, (d) definite pain on resisted extension of middle finger on 3 point
scale (none, some, definite with flinch): i, 18/53; ii, 24/53; iii, 20/58, (e)
definite pain on resisted extension of wrist on 3 point scale (none, some,
definite with flinch): i, 22/53; ii, 25/53; iii, 28/58, (f) definite tenderness of
lateral epicondyle on 3 point scale (none, some, definite with flinch): i, 23/53;
ii, 15/53; iii, 24/58, (g) disability: dressing: i, 32/53; ii, 29/53, iii, 31/58;
feeding: i, 41/53; ii, 44/53; iii, 42/58; washing: i, 38/53; ii, 41/53; iii, 45/58,
household tasks: i, 50/53; ii, 49/53; iii, 55/58; opening doors: i, 24/53; ii, 24/53;
iii, 26/58, carrying objects: i, 51/53; ii, 49/53; iii, 57/58; with work: i, 46/53; ii,
47/53; iii, 52/58, with sport: i, 36/53; ii, 35/53; iii, 42/58; (h) median pain
severity on 10 point Likert scale (IQR): i, 6 (4, 7); ii, 4 (2.8, 6.3); iii, 5 (4, 7); (l)
median impairment of function on 10 point Likert scale (IRQ): i, 4 (2, 5); ii, 4
(2, 5); iii, 4 (2, 5); (m) median severity of ‘main complaint’ on 10 point Likert
scale (IRQ): i, 6 (4, 7); ii, 5 (4, 7); iii, 5.5 (3, 7). Results after 4 weeks: (a)
Elbow pain today: i, 27/53; ii, 47/53; iii, 51/58, (b) pain every day for 1 week: i,
22/53; ii, 38/53; iii, 43/58; (c) pain for at least 1 day in past week: i, 30/53; ii,
50/53; iii, 55/58, (d) pain free grip strength . 300 mm Hg (average of two
readings with hand held dynamometer): i, 20/53; ii, 4/53; iii, 8/58; (e) pain on
extension of middle finger on 3 point scale (none, some, definite with flinch): i,
26/53; ii, 48/53, iii, 45/58; (f) pain on extension of wrist on 3 point scale (none,
some, definite with flinch): i, 19/53; ii, 45/53; iii, 47/58; (g) definite tenderness
of lateral epicondyle on 3 point scale (none, some, definite with flinch): i, 31/
53; ii, 49/53; iii, 53/58, (h) Disability: dressing: i, 11/53; ii, 30/53; iii, 28/58;
feeding: i, 20/53; ii, 34/53; iii, 35/58; washing: i, 20/53; ii, 33/53; iii, 39/58;
household tasks: i, 23/53; ii, 43/53; iii, 46/58; opening doors: i, 12/53; ii, 23/53;
iii, 23/58; carrying objects: i, 24/53; ii, 47/53; iii, 49/58; with work: i, 19/53; ii,
35/53; iii, 38/58; with sport: i, 20/53; ii, 31/53; iii, 33/58; (i) pain improvement
VAS (score #3): i, 41/53; ii, 25/53; iii, 28/58 better, (j) global measure of
improvement on 5 point scale (complete recovered, improved, no change,
worse, much worse): i, 22/53; ii, 3/53; iii, 2/58 completely recovered, (k)
median pain severity on 10 point Likert scale (IQR): i, 1 (0, 3); ii, 4 (2, 6); iii,
3.5 (2, 6); (l) median impairment of function on 10 point Likert scale (IQR): i, 0
(0, 2); ii, 3 (1, 5); iii, 2 (1, 4); (m) median severity of ‘main complaint’ on 10
point Likert scale (IRQ): i, 1 (0, 2); ii, 4 (1, 6); iii, 3 (1, 5). Results after 26
weeks: (a) Elbow pain today: i, 36/53; ii, 21/53; iii, 26/58; (b) pain every day
for 1 week: i, 28/53; ii, 16/53; iii, 19/58; (c) pain for at least 1 day in past week:
i, 46/53; ii, 29/53; iii, 37/58; (d) pain free grip strength . 300 mm Hg (average
of two readings with hand held dynamometer): i, 14/53; ii, 13/53; iii, 18/58; (e)
pain on extension of middle finger on 3 point scale (none, some, definite with
flinch): i, 38/53; ii, 27/53, iii; 32/58, (f) pain on extension of wrist on 3 point
scale (none, some, definite with flinch): i, 39/53; ii, 25/53; iii, 32/58; (g)
definite tenderness of lateral epicondyle on 3 point scale (none, some, definite
with flinch): i, 42/53; ii, 32/53; iii, 36/58; (h) Disability: dressing: i, 16/53; ii, 5/







































Study Methods Participants Interventions Outcome Notes
iii, 22/58; household tasks: i, 35/53; ii, 25/53; iii, 26/58; opening doors: i, 15/
53; ii, 4/53; iii, 7/58; carrying objects: i, 38/53; ii, 22/53; iii, 34/58; with work:
i, 28/53; ii, 19/53; iii, 24/58, with sport: i, 23/53; ii, 18/53; iii, 19/58; (i) VAS
pain scores (#3 ¼ better): i, 33/53; ii, 42/53; iii, 47/58 better; (j) median (IQR)
pain severity on 10 point Likert scale: i, 2 (1, 5); ii, 1 (0, 3); iii, 1 (0, 2.3); (k)
median (IQR) impairment of function on 10 point Likert scale: i, 1 (0, 3); ii, 0
(0, 2.8); iii, 0.5 (0, 2.8); (d) median (IQR) severity of ‘main complaint’ on 10
point Likert scale: i, 2 (0, 4), ii, 0 (0, 3), iii, 1 (0, 4). Results after 52 weeks: (a)
Elbow pain today: i, 24/53; ii, 18/53; iii, 20/57, (b) pain every day for 1 week: i,
17/53; ii, 12/53; iii, 12/57; (c) pain for at least 1 day in past week: i, 37/53; ii,
25/53; iii; 27/57; (d) pain free grip strength .300 mm Hg (average of two
readings with hand held dynamometer): i, 17/53; ii, 24/53; iii, 23/57, (e) pain
on extension of middle finger on 3 point scale (none, some, definite with
flinch): i, 25/53; ii, 24/53; iii, 21/57; (f) pain on extension of wrist on 3 point
scale (none, some, definite with flinch): i, 29/53; ii, 20/53; iii, 20/57, (g)
tenderness of lateral epicondyle on 3 point scale (none, some, definite with
flinch): i, 35/53; ii, 25/53; iii, 34/57; (h) Disability: dressing: i, 13/53; ii, 4/53;
iii, 9/57; feeding: i, 17/53; ii, 12/53, iii, 13/57; washing: i, 19/53; ii, 12/53; iii,
13/57; household tasks: i, 29/53; ii, 19/53; iii, 24/57; opening doors: i, 9/53; ii,
1/53; iii, 9/57; carrying objects: i, 32/53; ii, 24/53; iii, 30/57; with work: i, 23/
53; ii, 14/53; iii, 18/57; with sport: i, 18/53; ii, 14/53; iii, 15/57; (i) VAS pain
scores (#3 ¼ better): i, 43/53; ii, 45/53; iii, 44/57 better; (j) median (IQR) pain
severity on 10 point Likert scale: i, 1 (0, 2); ii, 0 (0, 2); iii, 0 (0, 2); (c) median
(IQR) impairment of function on 10 point Likert scale: i, 0 (0, 2); ii, 0 (0, 1); iii,
0 (0, 0); (d) median (IQR) severity of ‘main complaint’ on 10 point Likert
scale: i, 1 (0, 3.8); ii, 0 (0, 1.3); iii, 1 (0, 3.8). Other outcome measures: number





not described. Patient and




assessment at 1 and 4 weeks.
No information on drop-
outs.
37 patients with tennis elbow in secondary
care. Mean age: i, 41; ii, 43 years; women:
i, 4 (21%); ii, 3 (17%). No information on
in- and exclusion criteria.
i, 1 ml. (25 mg) hydrocortisone
acetate injection (n ¼ 19) ii, 1 ml.
procaine 2% (n ¼ 18). No
information on co-interventions.
Adverse effects: ii, increase of pain
for 24 h (number of patients is
unclear).
Results after 1 week: (a) global measure of improvement on 3 point scale
(improved, unchanged, worse): i, 14/19, ii, 7/18 improved. Results after 4
weeks: (a) global measure of improvement on 3 point scale (improved,










outcome assessor and care
provider blinded. Outcome
assessment at 30 days. No
information on drop-outs.
14 patients with epicondylitis in secondary
care. Mean (sd) age: i, 52 (9.5) years; ii,
45.6 (5.1) years; women: i, 6 (67%); ii, 5
(100%). Inclusion criteria: elbow pain for
more than 5 days, pressure pain, pain when
squeezing by patient, no evidence of intra-
articular involvement. Exclusion criteria:
osteochondritis dissecans, endocrinal
disorders, injection in preceding 6 months,
rheumatoid arthritis, Diabetes Mellitus.
i, 3 ml betamethason phosphate (3
mg) 1 2 ml lidocaine 2% injection
(n ¼ 9). ii, 3 ml betamethasone
acetate (3 mg) 1 2 ml lidocaine 2%
(n ¼ 5). No information on co-
interventions and adverse effects.
Baseline: (a) mean (sd) pain (VAS): i, 7.0 (2.1); ii, 4.6 (2.8); (b) mean (sd)
pressure pain (3 point scale): i, 2.4 (0.5); ii, 2.6 (0.5). Results after 5 weeks: (a)
mean (sd) pain (VAS): i, 1.4 (2.5); ii, 1.2 (1.6); (b) mean (sd) pressure pain (0–

































not described. Patient and
outcome assessor blinded.
No information on blinding
care provider. Outcome
assessment at 4, 8 and 24
weeks. Drop-outs: ii, one
patient after 4 weeks, i, two;
ii, three, iii, two patients
after 8 weeks, i, three, ii,
three, iii, four patients after
24 weeks.
89 patients with lateral epicondylitis in
secondary care. Median age (range): i, 47
years (34–64); ii, 47 years (19–62); iii, 46
years (32—62); women: i, 14 (48%); ii, 13
(43%); iii, 11 (38%); median duration
elbow complaints (range): i, 20 weeks (6–
150); ii, 36 weeks (6–154); iii, 16 weeks
(4–152). Inclusion criteria: history of pain
on gripping or extensor stress test together
with tenderness over the lateral epicondyle
or adjacent tissues. Exclusion criteria:
recent failed treatment, including
corticosteroid injections.
i, 2 ml hydrocortisone (25
mg) 1 lignocaine 1% (n ¼ 29); ii, 2
ml triamcinolone (10
mg) 1 lignocaine 1% (n ¼ 30) iii, 2
ml lignocaine 1% (n ¼ 29)
Injection repeated after 4 weeks if
necessary. No information on co-
interventions. Adverse effects: i, 17
(58%); ii, 13 (43%); iii, nine (11%)
patients had post-injection pain; i,
six (21%); ii, 12 (40%); iii, five
(17%) patients in whom skin
atrophy was observed.
Baseline: (a) mean (95% CI) pain VAS: i, 49 (41, 58); ii, 47 (39, 55); iii, 50 (42,
58); (b) mean (95% CI) tenderness score (0–3): i, 2.2 (2.0, 2.5); ii, 2.1 (1.8,
2.4); iii, 2.0 (1.7, 2.3); (c) mean (95% CI) pain weighted grip strength: i, 135
(106, 164); ii, 158 (128, 188); iii, 151 (119, 184). Results after 4 weeks: (a)
mean (95% CI) pain VAS: i, 28 (18, 38); ii, 17 (10, 25); iii, 46 (37, 55); (b)
mean (95% CI) tenderness score (0–3): i, 1.1 (0.7, 1.5); ii, 0.6 (0.3, 0.9); iii, 1.8
(1.4, 2.1); (c) mean (95% CI) pain weighted grip strength: i, 203 (169, 236); ii,
231 (202, 261); iii, 184 (153, 214). Results after 8 weeks: (a) mean VAS (95%
CI) pain: i, 30 (19, 41); ii, 20 (10, 30); iii, 35 (26, 43); (b) mean (95% CI)
tenderness score (0–3): i, 0.9 (0.5, 1.4); ii, 0.6 (0.3, 0.9); iii, 1.4 (1.0, 1.8); (c)
mean (95% CI) pain weighted grip strength: i, 200 (162, 237), ii, 238 (205,
272), iii, 201 (168, 234). Results after 24 weeks: (a) mean (95% CI) pain VAS:
i, 24 (14, 35); ii, 18 (7, 28); iii, 12 (8, 17); (b) mean (95% CI) tenderness score
(0–3): i, 0.9 (0.5, 1.3); ii, 0.6 (0.2, 1.0); iii, 0.7 (0.3, 1.1); (c) mean (95% CI)













not described. Patient and
outcome assessor blinded.
No information on blinding
care provider. Outcome
assessment at 4, 8 and 24
weeks. Drop-outs: i, two; ii,
four patients after 4 weeks;
i, six, ii, five patients after 8
weeks; i, three; ii, five
patients after 24 weeks.
57 patients with lateral epicondylitis in
secondary care. Median age (range): i, 47
years (30–61), ii, 45 years (28–65);
women: i, 18 (60%), ii, 15 (56%); median
duration elbow complaints (range): i, 24
weeks (3–100), ii, 24 weeks (4–150).
Inclusion criteria: history of pain on
gripping or extensor stress test together
with tenderness over the lateral epicondyle
or adjacent tissues. Exclusion criteria:
recent failed treatment, including
corticosteroid injections.
i, 2 ml triamcinolone (20
mg) 1 lignocaine 1% (n ¼ 30); ii, 2
ml triamcinolone (10
mg) 1 lignocaine 1% (n ¼ 27)
injection repeated after 4 weeks if
necessary. No information on co-
interventions. Adverse effects: i, 15
(50%); ii, 13 (48%) patients had
post-injection pain; i, eight (27%),
ii, five (18%) patients in whom skin
atrophy was observed.
Baseline: (a) mean (95% CI) pain VAS: i, 63 (59, 67); ii, 66 (60, 71); (b) mean
(95% CI) tenderness score (0-3): i, 2.3 (2.1, 2.6); ii, 2.2 (1.9, 2.6); (c) mean
(95% CI) pain weighted grip strength: i, 103 (85, 120); ii, 133 (98, 168).
Results after 4 weeks: (a) mean (95% CI) pain VAS: i, 28 (19, 37); ii, 27 (18,
37); (b) mean (95% CI) tenderness score (0–3): i, 0.8 (0.4, 1.1); ii, 0.6 (0.2,
0.9), (c) mean (95% CI) pain weighted grip strength: i, 200 (171, 230); ii, 228
(193, 263). Results after 8 weeks: (a) mean (95% CI) pain VAS: i, 22 (14, 31);
ii, 29 (17, 40); (b) mean (95% CI) tenderness score (0–3): i, 0.7 (0.4, 1.1); ii,
0.6 (0.2, 0.9); (c) mean (95% CI) pain weighted grip strength: i, 196 (159, 232);
ii, 211 (174, 247). Results after 24 weeks: (a) mean (95% CI) pain VAS: i, 33
(22, 45); ii, 35 (21, 48); (b) mean (95% CI) tenderness score (0–3): i, 0.8 (0.4,
1.2); ii, 0.8 (0.3, 1.3); (c) mean (95% CI) pain weighted grip strength: i, 193










assessor and care provider
not blinded. No information
on blinding patient.
Outcome assessment at 2
weeks. No information on
drop-outs.
21 patients with lateral epicondylitis in
secondary care. Mean age: 45 year,
women: 5 (24%). Inclusion criteria: typical
history, typical signs and symptoms of
epicondylitis of the humerus at the clinical
examination, e.g. pain during extension of
the wrist, impairment of mobility.
Exclusion criteria: no treatment in
previous 5 weeks.
i, 1.5 ml betamethasone (1
ml) 1 prilocaine (0.5 ml) injection
1 placebo naproxen tablets for 2
weeks (n ¼ 11). ii, naproxen tablets
(250 mg) twice a day for 2
weeks 1 1.5 ml local saline
injection (n ¼ 10). Co-
interventions: none. Adverse
effects: pain at the injection site in a
few cases (group unclear).
Baseline: (a) mean (sd) pain palpation (0–8): i, 5.4 (2.2); ii, 5.2 (1.6); (b) mean
(sd) pain during isometric wrist extension (0–8): i, 0.9 (1.3); ii, 0.9 (2.1); (c)
mean (sd) grip strength (mean of three squeezes of a Vigorimeter): i, 82.3
(33.6); ii, 66.3 (35.2). Results after 2 weeks: (a) mean (sd) pain palpation (0–8):
i, 4.5 (2.1); ii, 4.2 (2.8); (b) mean (sd) pain during isometric wrist extension (0–
8): i, 0.4 (0.5); ii, 1.1 (2.3); c) mean (sd) grip strength (mean of three squeezes
of a Vigorimeter): i, 84.0 (29.0); ii, 75.0 (36.8); (d) overall evaluation by (6
point Likert scale): i, 3/11; ii, 4/10 patients cured or markedly improved; (e)
overall evaluation by outcome assessor (4 point Likert scale): i, 5/11; ii, 5/10











































without strata or blocks.
Patient, outcome assessor
and care provider not
blinded for intervention.
Outcome assessment after 6
months and 1 year. Drop-
outs: i, one, ii, two patients
at 6 weeks.
106 patients with tennis elbow in
secondary care. Mean (sd) age in years: i,
42.6 (9.9); ii, 43.0 (8.5); women: i, 22
(42%); ii, 25 (47%); concomitant neck
complaints: i, 9 (17%); 15 (28%);
concomitant shoulder pain: i, 8 (15%); ii,
15 (28%); mean duration of elbow
complaints: 33 weeks (total group).
Inclusion criteria: pain at the lateral side of
the elbow, tenderness over the forearm
extensor origin, pain at the lateral
epicondyle during resisted dorsiflexion of
the wrist with the elbow in full extension.
Exclusion criteria: previous operation at
the lateral side of the elbow, arthritis or
allied conditions, neurological disorders of
the painful extremity, more than three
local corticosteroid injections within the
last 6 months, same elbow treated before
with Cyriax’ methods.
i, Local corticosteroid injection; 1
ml of triamcinolone acetate
suspension 1% 1 1 ml lidocaine
1%; repeated at 2 or 4 weeks if
necessary; one to three injections; 6
weeks (n ¼ 53). ii, Physiotherapy
by Cyriax: deep transverse friction
and Mills’ manipulation; thrice a
week; 12 treatments; 4 weeks;
followed by 2 weeks of restriction
of all painful activities (n ¼ 53). No
information on co-interventions.
Adverse effects: ii, one patient
discontinued the treatment because
of severe pain.
Baseline results: (a) Severity of pain (4 point scale): i, 0, ii, 0 patients pain
absent; (b) occurrence of pain (4 point scale): i, 0, ii, 0 patients never pain; (c)
Subjective loss of grip strength (4 point scale): i, 6 (11%); ii, 10 (19%) patients
pain absent; (d) pain provoked by resisted dorsiflexion of the wrist (absent,
slight, severe): i, 0, ii, 0 patients pain absent. Results after 6 weeks: (a) Severity
of pain (4 point scale): i, 22/52, ii, 3/51 patients pain absent; (b) occurrence of
pain (4 point scale): i, 22/52, ii, 3/51 patients never pain; (c) subjective loss of
grip strength (4 point scale): i, 32/52; ii, 13/51 patients pain absent; (d) pain
provoked by resisted dorsiflexion of the wrist (absent, slight, severe): i, 26/52;
ii, 5/51 patients pain absent; (e) patient satisfaction (3 point scale): i, 35/52; ii,
14/51 patients satisfied; (f) mean increase (decrease) in grip strength affected
limb(sd): i, 10.7 (14.9); ii, 2.3 (10.6); (g) mean increase (decrease) in grip
strength unaffected limb(sd): i, 21.8 (5.6); ii, 20.6 (8.7). Results after 52
weeks: (a) Severity of pain (4 point scale): i, 9/52, ii, 16/51 patients pain
absent; (b) occurrence of pain (4 point scale): i, 10/52, ii, 16/51 patients never
pain; (c) subjective loss of grip strength (4 point scale): i, 26/52, ii, 25/51
patients pain absent, (d) pain provoked by resisted dorsiflexion of the wrist
(absent, slight, severe): i, 16/52; ii, 23/51 patients pain absent; (e) patient
satisfaction (3 point scale): i, 26/52; ii, 30/51 patients satisfied, (f) mean (sd)
increase (decrease) in grip strength affected limb: i, 14.6(13.1); ii, 11.0(13.8);






injections at 6 weeks
and ‘negative’ at 1
year follow-up.
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